<DOC>
	<DOC>NCT01209195</DOC>
	<brief_summary>This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.</brief_summary>
	<brief_title>A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers</brief_title>
	<detailed_description>Successive cohorts of three or more patients were treated at escalating doses until a maximum tolerated dose/recommended phase 1 dose was identified. Once the maximum tolerated dose was identified, an Expansion Cohort was enrolled at that dose to further characterize safety and to explore pharmacodynamic endpoints.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Cytological or histological confirmation of locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or endometrial cancer; OR, cytological or histological confirmation of locally advanced /metastatic Her2 nonoverexpressing breast cancer Eighteen years of age or above Candidates for chemotherapy Able to understand and sign an informed consent (or have a legal representative who is able to do so) Measurable disease according to RECIST v1.1 ECOG Performance Score (PS) of ≤ 2 Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM121 Prior radiation therapy to &gt;25% of bone marrowbearing areas Evidence of any other active malignancy Active infection or fever&gt; 38.5°C during screening visits or on the first scheduled day of dosing Symptomatic CNS disease Known hypersensitivity to any of the components of MM121 or who have had hypersensitivity reactions to fully human monoclonal antibodies Received treatment, within 30 days prior to the first scheduled day of dosing, with any investigational agents that have not received regulatory approval for any indication or disease state Pregnant or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>HER-2 negative breast cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Fallopian tube cancer</keyword>
</DOC>